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Abstract
Background and Aim: In patients with cystic fibrosis (CF) the architecture of the developing
lungs and the ventilation of lung units are progressively affected, influencing intrapulmonary gas
mixing and gas exchange. We examined the long-term course of blood gas measurements in
relation to characteristics of lung function and the influence of different CFTR genotype upon this
process.
Methods: Serial annual measurements of PaO2 and PaCO2 assessed in relation to lung function,
providing functional residual capacity (FRCpleth), lung clearance index (LCI), trapped gas (VTG),
airway resistance (sReff), and forced expiratory indices (FEV1, FEF50), were collected in 178 children
(88 males; 90 females) with CF, over an age range of 5 to 18 years. Linear mixed model analysis and
binary logistic regression analysis were used to define predominant lung function parameters
influencing oxygenation and carbon dioxide elimination.
Results: PaO2 decreased linearly from age 5 to 18 years, and was mainly associated with FRCpleth,
(p < 0.0001), FEV1 (p < 0.001), FEF50 (p < 0.002), and LCI (p < 0.002), indicating that oxygenation
was associated with the degree of pulmonary hyperinflation, ventilation inhomogeneities and
impeded airway function. PaCO2 showed a transitory phase of low PaCO2 values, mainly during the
age range of 5 to 12 years. Both PaO2 and PaCO2 presented with different progression slopes
within specific CFTR genotypes.
Conclusion: In the long-term evaluation of gas exchange characteristics, an association with
different lung function patterns was found and was closely related to specific genotypes. Early
examination of blood gases may reveal hypocarbia, presumably reflecting compensatory
mechanisms to improve oxygenation.
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Background
Mixing of inspired gas is a prerequisite for effective respi-
ration and is dependent upon the architecture of the lung.
In children with cystic fibrosis (CF), the architecture of the
developing lungs and the ventilation of peripheral lung
units are progressively affected, influencing the efficiency
of gas mixing and gas exchange. We have previously
reported observations that inequalities in ventilation
occur significantly earlier in the course of lung function
decline than changes in other functional characteristics
[1]. Moreover, we have recently demonstrated in this Jour-
nal, that pulmonary hyperinflation and development of
trapped gas represent major functional features of disease
progression in children with CF [2]. In agreement with
several author groups, airway dysfunction and pulmonary
deterioration in CF is thought to be expressed by ventila-
tion inhomogeneities [1-6], pulmonary hyperinflation
[2,7] and gas trapping [2,8,9] occurring very early in life
[5,10,11]. The different patterns of functional derange-
ments stress the need to include a range of lung function
tests including gas exchange characteristics and to investi-
gate whether the CFTR genotype has an impact upon these
processes in CF patients, as has been previously reported
[12-14].
Limited knowledge exists as to whether gas exchange
parameters measured under resting conditions are helpful
in defining progression of lung disease in children with
CF. A correlation between survival and adequacy of gas
exchange, and the hypothesis that carbon dioxide reten-
tion may be a predictor of survival, was initially published
by Wagener et al. in 1980 [15]. Mechanisms of impaired
gas exchange and their influence on ventilation-perfusion
inequality through shunts have recently been studied by
Soni et al. [16]. A previous study of ours performed in a
limited number of children with advanced stages of CF
showed the interdependence of oxygenation, ventilation
inhomogeneities and trapped gas assemblage [8].
The aim of this prospectively acquired cohort study was to
evaluate the onset and course of deterioration of gas
exchange in relation to changes in lung volume, ventila-
tion distribution, trapped gas and airway obstruction, as
well as the influence of specific genotypes in CF patients,
from the 5th to the 18th year of life. Following up on our
recent work published in this Journal, we looked at the
long-term course of gas exchange characteristics in rela-
tion to different facettes of lung function [1,2].
Study population and methods
Bernese Cystic Fibrosis Patient Data Registry
Patients were recruited from the Bernese Cystic Fibrosis
Patient Data Registry, prospectively developed as an
extension of the American Cystic Fibrosis Patient Registry
founded by Warwick in 1966 [17]. Standard clinical and
biomedical parameters, as well as gas exchange character-
istics and lung function data of a total of 204 CF patients
regularly seen at the outpatient clinic between 1978 and
2008 are documented in the registry. The inclusion crite-
ria for the present study were: (i) CF diagnosis based on
the presence of characteristic phenotypic features [18], (ii)
confirmed by a duplicate quantitative pilocarpine ionto-
phoresis sweat test measuring both Na and Cl values > 60
mEq/L as well as by (iii) genotype identification using
extended mutation screening of both alleles [19,20], and
(iv) complete documentation of a minimum of 3 blood
gas analyses with concomitantly measured lung function
parameters performed annually between the ages of 5
to18 yrs, investigated during clinical stability. Twenty of
the 204 patients (9.8%) were younger than 6 years of age
(blood gas analysis and lung function data not available),
and in 6 CF patients (2.9%), fewer than 3 annual meas-
urements were available. Some of lung function data in
the database have been reported previously with respect
to the phenomenon of ventilation inhomogeneities [1]
and pulmonary hyperinflation [2], and the sensitization
against Aspergillus fumigatus [21]. There is no overlap with
previous publications with respect to the major topic of
the present report dealing with gas exchange characteris-
tics. This study protocol was approved by the Departmen-
tal Ethics Committee of the University Children's
Hospital Berne and by the Government Ethics Committee
of the State of Berne, Switzerland.
Pulmonary Function Measurements
Whole-body plethysmography and the multibreath nitro-
gen washout (MBNW) technique provided data pertain-
ing to functional residual capacity (FRCpleth, FRCMBNW),
lung clearance index (LCI), volume of trapped gas (VTG),
effective specific airway resistance (sReff), and forced expir-
atory indices (FEV1, FEF50). Measurement techniques have
been described in detail in previous papers [1,2,21]. All
values were expressed by z-transformation in standard
deviation scores (SDS), based on gender- and age-specific
regression equation [22-25], specifically calculated for
each lung function device as previously presented [1,2].
Full details concerning lung function techniques, calcula-
tion of SDS, and the statistical methods are given in the
additional file 1.
Blood Gas Analysis
In children, the preferred technique for routine blood gas
analysis is the sampling of arterialized capillary blood
from the earlobe [8,26,27], a technique that has been
established for clinical use and applied in various long-
term studies [28-31]. The accuracy of this technique
depends upon careful preparation of the earlobe [26],
puncture technique [26,27] and immediate analysis. Sev-
eral author groups have validated the accuracy of this par-
ticular technique for clinical and long-term evaluation ofRespiratory Research 2009, 10:106 http://respiratory-research.com/content/10/1/106
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gas exchange [26,27,32-34], provided certain important
methodological conditions are fulfilled. Therefore, oxy-
gen (PaO2) and carbon dioxide (PaCO2) tensions were
measured in arterialized blood collected from the ear lobe
[8,26,27,33] using a Radiometer ABL5, Copenhagen,
Denmark.
Blood gas sampling was performed after whole-body
plethysmography and before the multibreath nitrogen
washout measurements. The procedure was done in a
quiet atmosphere and our patients were familiar with the
process. The ear lobe was prepared according to the tech-
nique initially described [26,27], and previously estab-
lished in our laboratory [8]. Vasodilatation of the earlobe
was achieved by rubbing the lobe with a nicotinate paste
(Finalgon) [26,27,32,33] for at least 10 minutes and heat-
ing with an infrared lamp. During quiet breathing, the
arterialized blood was collected from a drop on the infe-
rior aspect of the earlobe, from which it was drawn into 3
thin heparinized glass capillary tubes by surface tension
under the guidance of a gloved finger over the open end
of the tube. The capillary tubes were then kept on ice until
aspiration into the gas analyzer, which was carried out
immediately after the blood draw.
Definitions of Gas Exchange Disturbance at Rest in 
Children
Details of the blood gas analysis performed by earlobe
puncture technique [8,26,27], and information on repro-
ducibility are given in the additional file 1. Most defini-
tions of hypoxemia are related to arterial blood gas values
obtained during exercise testing predominantly per-
formed in adult patients. There is no clearly defined cut-
off indicating gas exchange impairment at rest in children
with lung disease. Lamarre et al. [35], as well as Stokes et
al. [36] defined hypoxemia at rest in children as a PaO2
<80 mmHg. Gaultier et al. suggested defining hypoxemia
in children as less than 90% of predicted values [27,37].
We re-calculated the original data of Gaultier et al. using a
power function based on age in years and taking the 90 %
level of confidence of Gautier's predicted values. Accord-
ingly, the lower limit would be 78.3 mmHg for children
aged 6 years, and 81.9 mmHg for children aged 8 years
[27,37]. We therefore took a PaO2 level of 80 mmHg as
the lowest limit defining sufficient oxygen uptake [27].
Anthropometric data
Heights and weights were measured by experienced
nurses, using a Harpenden stadiometer and according to
recommended procedures [38]. The computation of lon-
gitudinal weight and height data was based on calculation
of age- and gender-corrected body mass index (BMI)
expressed as z-scores, using the method and values for
children reported by Cole et al [39].
Genotype Analysis
All patients were genotyped by a SSCP/HD scanning
method followed by direct sequencing of the variants,
thus permitting rapid and sensitive detection of 97-98 %
of known and novel (newly identified) CF mutations, as
previously described [19,40]. Genomic DNA was
extracted from EDTA blood samples using the QIAamp
Maxi Kit (Qiagen) according to the manufacturer's recom-
mendations and quantified by spectrophotometry. In
addition, a non-invasive method of buccal cell brushing
[20] was used to obtain DNA from premature infants,
recipients of previous blood transfusions and infants with
me meconium ileus. Mutation screening of the entire cod-
ing sequences of the CFTR gene (including the 27 exons
and exon/intron boundaries, intron 11 and 19, as well as
the promoter region) was performed in each patient using
a well-established single strand conformation polymor-
phism/heteroduplex (SSCP/HD) analysis.
Data Computation and Statistical Evaluation
Repeated serial measurements of lung function data,
acquired annually, were calculated as annual mean ± SEM
changes for presentation, and the statistical analysis
included procedures such as univariate regression proce-
dures, linear mixed model (LMM) analysis [41], and
binary logistic regression analysis, using SPSS (version 17,
SPSS Inc., Chicago, USA). Graphical presentation was
completed using Prism software (version 4.0, GraphPad
Software, Inc., San Diego, USA). In order to avoid poten-
tial confounding factors such as age at diagnosis, improve-
ment of management and/or treatment over the years of
observation as described by Soni et al [16], we assessed
the influence of these potential confounders by 3 charac-
teristics such as "year at birth", "year at diagnosis" and the
"year at testing". The "year at test" proved to be the prin-
cipal confounder influencing the course of PaO2 signifi-
cantly (t = 2.831; p = 0.005). Consequently, "year at test"
was taken as a covariate in all statistical analyses.
Linear Mixed Model Analysis (LMM)
The application of linear mixed model analysis evaluating
repeated measurements has several advantages. In con-
trast to General Linear Models (GLM), the time points at
which measurements are obtained need not be equal for
all subjects, and therefore, subjects with missing data are
not dropped from the analysis. In addition LMM analysis
features a single model for a repeated measurement
approach (i) assessing influences of various effects, (ii)
estimating these effects at each time point, and (iii) com-
paring them correctly against a background of between-
patient variation. There is no need to calculate mean val-
ues across all time points (to obtain the overall effect
influences), or to analyze time points separately (to
obtain specific effects at each time point). Standard errors
for effects at individual time points are calculated usingRespiratory Research 2009, 10:106 http://respiratory-research.com/content/10/1/106
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information from all time points and are, therefore, more
robust than standard errors calculated from separate time
points. Finally, the covariance pattern of the repeated
measurements can be determined and taken into account
(e.g. the model can figure out whether measurements are
correlated across all time points, or whether they show
more complex pattern over time) [42]. These are impor-
tant advantages especially for observational studies,
where people often miss regularly scheduled clinic
appointments or experimental sessions. In addition, LMM
analysis offers the possibility to select the best variance-
covariance structure for repeated measurement data, and
interactions of interest can be specified [43]. More details
to the discussion LMM versus GLM analysis are given in
the additional file 1, under the heading "Options of Statis-
tical Modeling".
Results
Characteristics of Study Population
The inclusion criteria were fulfilled for a patient cohort of
178 CF patients (88 males; 90 females) recruited from the
Bernese CF Registry (87.3%). Their follow-up statistics
and the distribution of CFTR mutations are given in Table
1. From the entire database, 26 patients (12.7%) were
excluded from evaluation because of insufficient number
of tests (<3 per year) or an age younger than 5 years. Of
these 178 CF patients, 14 (6.9%) died during the observa-
tion period with a mean age (range) at death of 16.4 ± 5.9
(8.6 to 24.2) years. One girl died in a car accident and the
remaining patients had a PaO2 of 56.5 (49.4 to 63.1)
mmHg, and a PaCO2 of 40.8 (36.2 to 46.8) mmHg in the
last year of life. The individual follow-up data of these CF
patients who died during the observation period are given
in the additional file 1.
All patients except 3 suffered from pancreatic insuffi-
ciency. P. aeruginosa infection was present in 111 patients
(67.7 %), with a mean age at onset of 5.7 years (range 0.1
to 20.5 years). Twenty-three patients were intermittently
colonized and 30 remained free from P. aeruginosa coloni-
zation. Five patients underwent lung transplantation and
in 2 the liver was transplanted. Within this study cohort of
patients, a total of 1457 tests were performed representing
a median (range) of 8.1 (3-15) test sets per child, or 68.2
(37-90) test sets per year of observation. Gender was
equally distributed. According to the frequencies in our
Table 1: Patient cohort (A), data base characteristics (B), and distribution of CFTR mutations (C) taken from the Bernese CF Registry 
(n = 178, 87.3% of a total number of 204 CF patients)
A
Patient cohort follow-up statistics
Gender distribution of patients Blood gas tests within age periods
n%
- males 88 49.4 5 to 8 y 427/1457 29,3%
- females 90 50.6 9 to 14 y 527/1457 36.2%
178 100 15 to 18 y 503/1457 34.5%
From entire database, 26 patients (12.7%) excluded because of insufficient number of tests, (6) or age < 6 years (20)
B
Blood gas test and lung function measurement follow-up statistics
Number of blood gas tests median (range) Blood gas tests per year of observation
Total of tests 1457 1987 to 1993 326/1457 22.4%
per child 8.1 (3-15) 1994 to 2000 539/1457 37.0%
per year of observation 68.2 (37-90) 2001 to 2008 592/1457 40.6%
C
Distribution of CFTR mutations
n%
Inframe/inframe (F508del[2]) a 103 57.9
Inframe/nonsense b 22 12.4
Frameshift/F508del c 19 10.7
Frameshift/non-F508del d 12 6.7
Inframe/splicesite e 7 3.9
Miscellaneous f 15 8.4
Total 178 100.0
Equal distribution of CFTR genotypes over age range and over years of observation
CFTR: cystic fibrosis transmembrane regulatorRespiratory Research 2009, 10:106 http://respiratory-research.com/content/10/1/106
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population-specific  CFTR  genotype distribution, the
patients were stratified into 6 groups consisting of (a)
F508del homozygotes F508del[2| (inframe/inframe): n =
103 (57.9%), (b) R553X, G542X, Q525X and E585X com-
pound heterozygotes with F508del (inframe/nonsense
mutations): n = 22, (12.4%), (c) 3905insT compound
heterozygotes 3905insT/F508del (frameshift/F508del): n
= 19, (10.7%), (d) 3905insT compound heterozygotes
with other than F508del (frameshift/non-F508del): n =
12, (6.7%), (e) 1717-1G>A, 621+1G<T and 4005+1G>A
compound heterozygotes with F508del (inframe/splices-
ite): n = 7 (3.9%), and (f) miscellaneous genotypes n = 15,
(8.4%). The genotypes were equally distributed over the
age-range studied and the years of observation.
Deterioration of Gas Exchange Characteristics related to 
Age
In Figure 1 age-related annual changes of PaO2 and PaCO2
(mean ± SEM) are shown, and in the following section
some aspects of hypoxemia, hypercapnia, as well as a new
phenomenon of hypocarbia are presented.
Hypoxemia. Overall PaO2 presented with a linear decline
from a mean ± SEM of 80.7 ± 1.9 mmHg at 5 years of age
to a mean of 69.9 ± 1.6 mmHg at age 18 years. As FEV1 is
the most commonly used lung function parameter inter-
nationally, the figure additionally shows the PaO2 decline
within 2 subgroups stratified according to normal FEV1 (z-
score > -2 SDS) or abnormal FEV1 (z-score < -2 SDS). The
measurements within the 2 subgroups were equally dis-
tributed over the age range studied. Unpaired t-test with
Welch' correction compared PaO2  measurements with
normal FEV1 (46.8%) presenting a mean ± SEM oxygena-
tion of 76.9 ± 0.62 mmHg versus PaO2 measurements
with a FEV1 <-2 SDS with a mean oxygenation of 70.2 ±
0.70 mmHg This significant difference in PaO2 decline
was mainly due to a mean difference of 6.7 ± 0.94 mmHg
between the FEV1-subgroups (p < 0.0001) and not to a dif-
ference in their slopes.
The annual changes in PaCO2 demonstrated a more com-
plex course. The mean PaCO2 of 33.2 ± 0.45 mmHg at 5
years of age showed a transient stagnation in a large pro-
portion of patients before rising to a mean of 36.1 ± 0.47
mmHg at the age of 18 years. This phenomenon of low
PaCO2 measurements was observed in 103 of the 164
patients (62.8%), mainly associated with a FEV1 > -2SDS,
and occurred over an age range of 5.8 to 15.8 years. An
unpaired t-test with Welch' correction comparing PaCO2
measurements with a mean PaCO2 of 33.7 ± 0.32 mmHg
for blood gas measurements associated with normal FEV1
versus a mean PaCO2 of 35.1 ± 0.29 mmHg in association
with abnormal FEV1 also revealed a significantly different
PaCO2 course with a mean difference of 2.4 ± 0.6 mmHg
between the FEV1-subgroups (p = 0.0002).
Hypercapnia, defined as a PaCO2 >45 mmHg at rest, was
observed only in a few patients in our collective. In con-
trast, we were surprised by some very low PaCO2 values
occurring during the course between ages 5 to 12 years
(Figure 1).
Hypocarbia, and especially a lower level for PaCO2 at rest
in children has not yet been defined internationally.
Using three different statistical techniques (binary logistic
regression, ROC and discriminant analysis) explained in
detail in the additional file 1, hypocarbia was defined as a
PaCO2 less than or equal to 34 mmHg.
Associations with Genotype
A potential association between gas exchange characteris-
tics and genotypes was investigated. Data from the most
Annual changes of gas exchange characteristics (PaO2,  PaCO2) shown as mean ± SEM of repeated annual measure- ments over the age range 5 to 18 years (halftone symbols),  stratified into measurements concomitantly obtained under  normal FEV1 > -2 SDS (open symbols) and abnormal, FEV1 < - 2 SDS solid symbols Figure 1
Annual changes of gas exchange characteristics 
(PaO2, PaCO2) shown as mean ± SEM of repeated 
annual measurements over the age range 5 to 18 
years (halftone symbols), stratified into measure-
ments concomitantly obtained under normal FEV1 > 
-2 SDS (open symbols) and abnormal, FEV1 < -2 SDS 
solid symbols. Measurement numbers (n) are given along 
the x-axis.Respiratory Research 2009, 10:106 http://respiratory-research.com/content/10/1/106
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frequent CFTR genotypes inframe/inframe (F508del[2]),
inframe/nonsense mutations (F508del/R553X, F508del/
G542X, F508del/Q524, F508del/E553), inframe/
frameshift (mainly F508del/3905insT), non-F508del/
frameshift, (mainly non-F508del/3905insT) and inframe/
splicesite genotypes were incorporated as fixed effects
with "age at time of annual test" as covariate, and the
patient-specific intercept as a random effect. The remain-
ing miscellaneous genotypes were excluded from the
model. For all five subgroups, distribution of measure-
ments was equally dispersed over the age range studied,
and the distribution of measurements over the age range
within the subgroups of genotypes is given in the addi-
tional file 1. Based on LMM analysis, Figure 2 (panel A)
demonstrates that different slopes of gas exchange charac-
teristics were found in the five genetic groups. F508del/
frameshift started with the lowest PaO2 mean values at age
6 years (72.3 ± 1.5 mmHg), and decreased to the lowest
mean values at the age of 18 years (68.1 ± 1.7 mmHg),
whereas F508del[2] and inframe/nonsense showed only
slightly reduced oxygenation (77.1 ± 0.67, 76.9 ± 1.4
mmHg, resp.) starting at the age of 6 years, but demon-
strated the most significant deterioration over the years.
Interestingly, frameshift/non_F508del and inframe/
splicesite, presented with significantly milder progression
(p < 0.05). Comparisons were significant with respect to
the intercept between frame/F508del and F508del[2] (p <
0.0001) and inframe/nonsense (p  < 0.005) as well as
between F508del/frame and non-F508del/frame (p  =
0.013). Otherwise, PaCO2 (panel B) increased from 32.9
± 0.3 mmHg (F508del[2|), 33.1 ± 0.6 mmHg (inframe/
nonsense), 33.7 ± 0.7 mmHg (frameshift), up to 35.9 ±
0.3 mmHg, 37.2 ± 0.6 mmHg, 36.0 ± 0.6, respectively,
where as inframe/splicesite and non_F508del/framshift
remained within the range of lower PaCO2 (p < 0.001).
Association between Gas Exchange and Lung Function
LMM analyses was used to evaluate a potential interrela-
tionship between gas exchange measurements over age
and lung function, taking PaO2 as outcome measures and
Progression with age based on measurements of A) PaO2 and B) PaCO2 within the 5 genetic subgroups (miscellaneous  excluded), obtained by linear mixed model LMM analysis Figure 2
Progression with age based on measurements of A) PaO2 and B) PaCO2 within the 5 genetic subgroups (mis-
cellaneous excluded), obtained by linear mixed model LMM analysis. Patient numbers are given by N, measurement 
numbers by n. Data distribution over age was equal for each genetic subgroup.Respiratory Research 2009, 10:106 http://respiratory-research.com/content/10/1/106
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FRCpleth, LCI, VTG, sReff, FEV1, FEF50, BMI as explanatory
variables, adjusted by the "year at testing" as covariate.
Table 2 shows that PaO2 was significantly associated with
FRCpleth (t-statistics -5.575; p < 0.0001), FEV1 (t-statistics
3.451; p = 0.001), FEF50 (t-statistics 3.158; p = 0.002), and
LCI (t-statistics -3.156; p = 0,002), but not with VTG, sReff,
or BMI.
We evaluated the early onset of abnormal lung function
in relation to oxygenation. For that purpose mean values
of lung function data were computed for the age range of
5 to 8 years for each patient. 120 CF patients, who had a
mean of at least 2 measurements of all lung function
parameters, were eligible. Hypoxemia at rest was defined
as a PaO2 <80 mmHg as described by Lamarre et al. [35].
Using a two-test analysis by z-score, comparisons of PaO2
with chi-square statistics (cross tabulation) demonstrated
that the best association was found for FRCpleth (Chi-
square: 21.288; p  < 0.0001), followed by FEF50 (Chi-
square: 15.579; p < 0.0001), sReff (Chi-square: 11.894; p =
0.001), FEV1 (Chi-square: 10.33; p = 0.001), and LCI (Chi-
square: 9.644; p = 0.002). VTG was not significantly associ-
ated. The association between oxygenation and pulmo-
nary hyperinflation is presented in Figure 3 (panel A). In
39.2 % of patients hypoxemia (PaO2 < 80 mmHg) was
associated with pulmonary hyperinflation (FRCpleth  >
2SDS; dashed area). A further 36.7 % of patients pre-
sented with hypoxemia without pulmonary hyperinfla-
tion. As FEV1 is still considered to be one of the best
predictors of progression in CF, we investigated whether a
differentiation between normoxemia and hypoxemia can
be correlated with this spirometric function parameter.
Figure 3, panel B demonstrates that 40.0 % of patients
presented with a normal FEV1, while hypoxemia was
already present (dashed area). It is noteworthy that these
patients already had a significant deficit in oxygenation as
shown by the PaO2, while FEV1 remained within normal
limits,
Under the condition of normocarbia, PaCO2 was mainly
correlated with FEV1 (p < 0.0001), and like PaO2, less with
VTG (p = 0.004) and sReff (p = 0.003). In contrast, if hypoc-
arbia was detected, a significant association of PaCO2 with
FEV1 (p < 0.0001) and FEF50 (p < 0.0001) could be found,
as well as with BMI (p = 0.011) and FRCpleth (p = 0.013).
In Figure 4 stratification of measurements was performed
for normocarbia versus  hypocarbia, divided into those
with normal versus abnormal FEV1 in relation to oxygena-
tion. The question arose whether or not patients present-
ing with hypocarbia have an advantage with respect to
oxygenation. It could be shown, that oxygenation was
improved under the condition of hypocarbia, especially if
forced expiratory volume was normal (p < 0.0001).
Discussion
The present observational study illustrates the complexity
of gas exchange in children with cystic fibrosis, especially
with reference to the age-related changes in oxygenation.
The age-related deterioration of oxygenation has not yet
been well described, presumably due to the fact that gas
exchange characteristics are not routinely evaluated over a
period of a substantial number of years. Our study, per-
formed in a representative number of cases and followed-
up over a consistent number of years demonstrates that
Table 2: Univariate and multivariate linear mixed model (LMM) analysis evaluating lung function parameters as explanatory variables 
of PaO2, including adjustment by "year at testing"
LMM univariate analysis adjusted for age and test year
Coefficient 95 % CI p
FRCpleth(SDS) -1.641 -1.907 to -1.376 < 0.0001
LCI (SDS) -0.338 -0.403 to -0.272 < 0.0001
VTG (SDS) -1.209 -1.471 to -0.947 < 0.0001
sReff (SDS) -0.517 -0.599 to -0.434 < 0.0001
FEV1 (SDS) 1.126 0.991 to 1.261 < 0.0001
FEF50 (SDS) 0.586 0.507 to 0.664 < 0.0001
BMI (SDS) 1.374 0.922 to 1.825 < 0.0001
LMM multivariate analysis with backward elimination procedure*
Coefficient 95 % CI p
FRCpleth(SDS) -0.868 -1.180 to -0.5555 < 0.0001
LCI (SDS) -0.125 -0.191 to -0.058 < 0.0001
sReff (SDS) -0.123 -0.225 to -0.021 0.019
FEV1 (SDS) 0.511 0.284 to 0.738 < 0.0001
FEF50 (SDS) 0.161 0.0412 to 0.281 0.008
* VTG and BMI excluded from modelRespiratory Research 2009, 10:106 http://respiratory-research.com/content/10/1/106
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oxygenation is specifically influenced by different lung
function deficits and CF genotypes. There are several
major findings of this study: First, (i) a linear decline in
oxygenation could be demonstrated over the age range 5
to 18 years, which was closely and independently related
to the degree of pulmonary hyperinflation (FRCpleth), the
degree of flow and volume limitation (FEV1, FEF50), and
ventilation inhomogeneities (LCI). Secondly, (ii) as
reported for several lung function parameters [1,2], the
decline in PaO2 is representative of an overall deteriora-
tion of lung disease, reflecting that factors such as the
degree of pulmonary hyperinflation, ventilation inhomo-
geneities and impeded airway function are involved in the
long-term course of gas exchange characteristics. Most
importantly, however, (iii) in more than half the patients
with hypoxemia, FEV1 was within the range of normal val-
ues, and hence with functional deficits not detectable by
spirometric lung function testing alone. Furthermore, (iv)
an association could be found between oxygenation and
the genotype. The so called "Swiss-Type" (3905insT/
F508del), presented with the worst PaO2 values already
detectable at the age of 5 years and the subgroup R553X/
F508del showed the worst deterioration (steepest slope)
over the age range studied. Interestingly, some special
subgroups of genotypes (inframe/splicesite, 3905insT/
non-F508del) showed only discrete changes in gas
exchange over the years. It follows that PaO2 may serve as
a sensitive marker of lung function deterioration in CF.
The present study demonstrates that the preservation of
airway function and hence an intact static recoil of the
lungs over years is essential, as has been shown by Zaple-
tal [44]. It was reported by Hart et al. that if FEV1 declines
in children and young adults with CF, there is an increase
in the elastic load and work of breathing, resulting in a
rapid shallow breathing pattern, that is associated with
further impairment of gas exchange [28]. Pulmonary
hyperinflation and ventilation inhomogeneities are fur-
ther pathophysiologic characteristics, which have to be
taken into consideration regarding progression in CF, as
reported previously by our group [1,2].
Limitations of this Study
A detailed discussion about blood gas measurements in
children, the stratification into genetic subgroups, limita-
tions in the interpretation of extensive lung function tests
and the different options for statistical modeling are given
in the additional file 1. An important limitation of this
type of data resides in the ability to obtain repeated meas-
urements of lung function annually over a substantial
period of time. Noteworthy therefore, we were able to
obtain serial annual measurements over a 10-year period
in 62 % of the patients. Although the technique of blood
gas measurements from the arterialized earlobe is well
established and routinely used in several laboratories
[26,27,32-34], in the following some technical aspects
have to be mentioned. Finally, limitation of collected
Crosstab comparison of initial z-scores (mean during age range of 5 to 8 years) between A), PaO2 and FRCpleth presenting pul- monary hyperinflation in association with hypoxemia and B) PaO2 and FEV1, to present the portion of normal FEV1 measure- ments while already hypoxemic, obtained in 120 CF patients Figure 3
Crosstab comparison of initial z-scores (mean during age range of 5 to 8 years) between A), PaO2 and FRCpleth 
presenting pulmonary hyperinflation in association with hypoxemia and B) PaO2 and FEV1, to present the por-
tion of normal FEV1 measurements while already hypoxemic, obtained in 120 CF patients.Respiratory Research 2009, 10:106 http://respiratory-research.com/content/10/1/106
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functional data over a wide range of years may include
confounders related to changes in the technical set-up. As
proposed by Soni et al [16], we assessed the influence of
these potential confounders by 3 characteristics such as
"year at birth", "year at diagnosis" and the "year at test-
ing". The "year at test" proved to be the principal con-
founder influencing the course of PaO2. Most important
finally, the variances of lung function over age are specific
for each lung function parameter. Therefore, values of
lung function data have to be expressed by z-scores, calcu-
lated from age- and gender-specific equations for value
prediction for each lung function parameter, and in par-
ticular also for each lung function device as previously
presented [1,2].
Blood gas measurements in children
Currently direct arterial catheterization of the radial artery
is the widely accepted gold standard technique for obtain-
ing the most accurate assessment of pulmonary gas
exchange, especially in adult medicine. However, this
technique is painful and not suitable for use in children
for long-term evaluation. Alternative non-invasive meth-
ods have been proposed such as pulse oxymetry, which is
used to assess arterial oxyhemoglobin saturation. How-
ever, obtained values correlated poorly with arterial PaO2
values [33]. Pulse oxymetry is a poor predictor of PaO2
because of the sigmoidal shape of the oxyhemoglobin dis-
sociation curve and because the curve can be shifted under
various clinical and physiological conditions. Therefore,
capillary arterialized blood gas analysis is a very conven-
ient technique especially suitable for children and for
repeated measurements. Comparisons between earlobe
capillary PaO2 and radial arterial PaO2 were performed by
Godfrey et al. [26] and Gaultier et al. [27]. The former
author group compared earlobe and arterial values in 8
adult subjects (age range of 26 to 63 years) at rest and on
exercise, showing that the mean difference between arte-
rial and earlobe samples for PaO2 at rest was 2.09 ± 2.48
mmHg and for PaCO2 0.65 ± 1.2. Gaultier et al. [27] stud-
ied these differences in 70 infants or children suffering
from cardiac or pulmonary disease and demonstrated sig-
nificant differences in PaO2 of 1.86 ± 0.60 mmHg only in
children younger than 8 years. It was concluded that sam-
pling blood from the earlobe is appropriate as a substitute
for arterial PaO2, provided certain important methodo-
logical conditions such as sampling site and optimal
vasodilatation are fulfilled. In a study examining PaO2
measurements over a long period of time, it would be
preferable to validate the results periodically using arterial
samples. It is, however, difficult to justify arterial blood
sampling in a collective of CF children with no or only
minor pulmonary function impairments. In a meta-anal-
ysis performed by Zavorsky et al. [34], it was shown that
capillary blood gases accurately reflect arterial blood sam-
ples and that sampling blood from the earlobe is appro-
priate as an alternative to arterial PaO2. However, the
discrepancy between capillary and arterial PaO2 increased
with increasing PaO2. Reproducibility of earlobe blood
gas measurements was assessed by Godfrey et al. [26] and
Gaultier et al. [27].
Oxygenation and Lung Function
There is only limited knowledge about the relationship
between oxygenation and factors such as the degree of
pulmonary hyperinflation, ventilation inhomogeneities
and/or airway function under resting conditions in CF.
Moreover, hypocarbia in CF is poorly described in the lit-
erature and the correlation of gas exchange characteristics
with lung function is unknown. There is only one report
in which the association between hypocarbia and hyper-
capnia and the matching of ventilation has been studied
in dogs [45]. The present report focuses on the decline of
oxygenation in CF. As demonstrated in Table 2, oxygena-
tion is significantly associated with the degree of flow lim-
itation given by the FEV1. This finding is in line with
Hirsch et al., who could demonstrate a higher ventilatory
equivalent in CF patients in comparison with control sub-
Crosstab comparison of initial z-scores of FEV1 (mean during  age range of 5 to 8 years) and oxygenation under 4 different  conditions: (i) decreased airway patency (FEV1 < -2SDS) and  normocarbia (PaCO2 > = 34 mmHg), (ii) normal airway pat- ency and normocarbia, (iii) decreased airway patency and  hypocarbia, and (iv) normal airway patency and hypocarbia Figure 4
Crosstab comparison of initial z-scores of FEV1 
(mean during age range of 5 to 8 years) and oxygena-
tion under 4 different conditions: (i) decreased air-
way patency (FEV1 < -2SDS) and normocarbia 
(PaCO2 > = 34 mmHg), (ii) normal airway patency 
and normocarbia, (iii) decreased airway patency and 
hypocarbia, and (iv) normal airway patency and 
hypocarbia.Respiratory Research 2009, 10:106 http://respiratory-research.com/content/10/1/106
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jects, suggesting increased work of breathing due to air-
flow obstruction and dead space ventilation. Ventilation
appears mechanically inefficient but necessary to keep
arterial PaCO2 from rising and oxygen saturation from
falling at rest [46]. Moreover, Hart et al. showed that in
children and young adults with advanced stable pulmo-
nary CF disease, falling FEV1 induced an increase in the
respiratory muscle load, predominately by a decrease in
lung compliance (CLdyn) rather than an increase in total
lung resistance (RL). Other physiologic studies have dem-
onstrated an increase in tidal volume (VT) with a reduc-
tion in respiratory rate (RR) in association with
impairment of gas exchange [28]. The present study indi-
cates that oxygenation at rest is significantly associated
with LCI and with FRCpleth and reduced forced expiratory
volume (FEV1) as an indirect parameter of airflow limita-
tion.
Genotype Association with Gas Exchange Characteristics
To date, a relationship between CFTR  genotypes and
severity of pulmonary disease has proven difficult to
determine [47]. The present study, however, clearly dem-
onstrates an association between gas exchange character-
istics (especially oxygenation) and genotypes. These
findings are in line with previous work obtained in infants
[13] and children [1,2] with CF. Schaedel et al. used FEV1
in terms of % predicted of normal, to demonstrate a
slower rate of decline in patients with missense mutations
compared with F508del homozygotes [14]. Since these
patients generally had a sufficient level of pancreatic func-
tion, it was concluded that CFTR  genotypes associated
with long-term pancreatic sufficiency have more benign
lung disease and better pulmonary function [12,14]. With
the exception of one patient with a missense mutation, all
patients in our study collective presented with pancreatic
insufficiency, requiring continuous supplementation with
pancreatic enzymes and high caloric nutritional support.
The major new finding in the present study is an alloca-
tion of specific genotypes to (i) sufficient oxygenation
combined with low PaCO2 levels, and (ii) insufficient
oxygenation combined with normocarbia, reflecting dif-
ferent phenotypes of disease progression. Inframe/splices-
ite and non-F508del/frameshift mutations seem to have a
significant better gas exchange pattern than the other
groups. The different progression between F508del/
frameshift and non-F508del/frameshift is especially strik-
ing. Based on recent findings [48] showing complete lack
of  CFTR  protein at the apical membrane in F508del/
3905insT compound heterozygous patients, we hypothe-
size that there may be an interaction between the plasma
membrane resulting in a more severe phenotype. How-
ever, further experiments are needed to elucidate the fate
of the 3905insT protein in the cell after its biosynthesis.
In conclusion, the linear decline of PaO2 over the years
was closely associated with the degree of pulmonary
hyperinflation, ventilation inhomogeneities, and parame-
ters of airway function on the one hand and with geno-
types on the other hand. We found that gas exchange
characteristics (PaO2, PaCO2) are very sensitive parame-
ters of deterioration in CF lung disease. Since the assess-
ment of factors influencing the overall estimate of gas
exchange is of major interest to understand functional
deficits influencing progression not only in quantitative,
but also in qualitative terms, classification into certain
functional risk groups may have implications for thera-
peutical intervention. However, further studies are needed
to demonstrate whether changes in PaCO2 in relation to
PaO2 are potential predictors of exacerbation or of the
long-term clinical outcome. We keep in mind, that the
ability of blood gas measurements to serve as outcome
measures in interventional studies largely depends from
the knowledge to what extent changes recorded during a
short-term study will be out of the variability of the meas-
urement changes established by the present long term
approach over years.
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